Lacosamide Viatris

Lacosamide, the active ingredient in Lacosamide Viatris, is an anti‑epileptic presented as an oral formulation for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy.

GNH USA supplies Lacosamide Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anti‑epileptic drug used to manage focal seizure disorders.

- Partial‑onset seizures: reduces seizure frequency in patients with focal epilepsy. - Adjunct therapy in epilepsy: used alongside other anti‑epileptic drugs to improve overall seizure control. - Focal epilepsy: helps control seizures that originate in a specific brain region.

Lacosamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: feeling of stomach upset or urge to vomit. - Fatigue: unusual tiredness or lack of energy. - Headache: mild to moderate head pain. - Blurred vision: temporary visual disturbances. - Diplopia: double vision.

Serious or Rare Side Effects: - Suicidal thoughts: emergence of depressive ideation or self‑harm urges. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmia: abnormal heart rhythm, including PR‑interval prolongation. - Respiratory depression: slowed breathing, especially with CNS depressants. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Liver injury: elevated liver enzymes or hepatitis.

Before initiating therapy, clinicians should consider several safety factors.

- Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution and observe liver function tests. - Concomitant CNS depressants: observe for enhanced sedation or respiratory effects. - History of cardiac arrhythmia: evaluate cardiac status prior to use. - Pregnancy: safety not established; avoid unless benefits outweigh potential risks. - Store below 25°C: keep in the original pack, protect from moisture.

Lacosamide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., carbamazepine): may reduce lacosamide effectiveness. - Other sodium‑channel blockers: may heighten risk of central nervous system depression.

Moderate Interactions (Monitor Closely): - Co‑administration with other antiepileptic drugs: may require therapeutic drug monitoring. - Alcohol consumption: can amplify dizziness and sedation. - Anticoagulants: may increase bleeding tendency; monitor coagulation parameters.